Reviva completed a Phase 3 study on brilaroxazine for schizophrenia.
The study showed sustained efficacy and a well-tolerated safety profile.
6 Likes
The stock of Reviva is down 10 percent as of now. I wonder what is going on?
2 Likes
https://revivapharma.com/reviva-announces-positive-full-dataset-for-1-year-phase-3-recover-open-label-extension-study-evaluating-brilaroxazine-in-schizophrenia/
The results were very impressive, including for negative symptoms. Total PANSS drop excluding placebo comparison was quite large. The company may or may not have enough money to conduct last clinical trial needed. In addition, new government regulatory standards for the FDA might be tricky. Also the company announced it was trying to sell millions of new stock shares to raise money. New shares dilute the ownership percent for those already owning shares.
3 Likes